DuPont de Nemours, Inc. (DD) Stock Analysis

58.0/100
Hold Not Halal Basic Materials
Price $153.78
Market Cap $20.38B
52-Week Change +26.26%

Is DD a good investment?

DuPont de Nemours, Inc. (DD) has a Plutrex AI rating of 58.0/100 as of November 13, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Fortress balance sheet with D/E 0.23x (73.6% below industry 0.87x), $1.652B cash, and $883M FCF — real cash generation that dramatically exceeds GAAP net income and funds PFAS settlements, dividends, and buybacks simultaneously without credit market access; FCF capitalized at 7-8% implies $11-12.6B enterprise value. Main concern: Valuation remains deeply stretched at current price: P/E 69.92x vs. industry 24.90x (+180.8% premium), PEG 3.29x vs. industry 2.91x (+12.9% premium), with analyst consensus target $164.50 implying only 6.3% upside — the stock has rallied +10% from my prior observation with no proportional fundamental improvement; every 1% further rally narrows the already paper-thin margin of safety.

Investment Summary

DuPont (DD) at $154.70 presents a fundamentally sound business trapped in an unjustifiable valuation. The company generates $883M in FCF, maintains a fortress balance sheet (D/E 0.23x vs. industry 0.87x), and leads its Chemicals sector peers on gross margin (31.6% vs. 17.25% industry), operating margin (14.4% vs. 8.28%), and forward EPS growth (+10.0% vs. -5.55% industry). However, the stock has now rallied +10.0% from my prior $140.58 observation — a move that has not been accompanied by any proportional fundamental improvement. The analyst consensus target of $164.50 implies only 6.3% upside, an unacceptably thin margin of safety at this price. Importantly, the P/E has collapsed dramatically from 333x to 69.92x, and the PEG from 16.45x to 3.29x — a normalization that largely reflects denominator improvement (EPS recovery) rather than the stock becoming cheap. The PEG of 3.29x remains well above the fair-value threshold of 1.0x, and the +180.8% P/E premium vs. the industry average of 24.90x is extreme. The news backdrop is positive: headline 'DuPont raises full-year profit forecasts on strong healthcare, aerospace demand' confirms earnings outperformance, and Microsoft/NobleAI collaboration signals innovation pipeline strength. But positive news is already priced into a +10% move from my prior entry zone. This is NOT an entry point — it is a reason to wait for a pullback.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
85/100
Growth Potential
53/100
Valuation
22/100
Profitability
58/100
Debt Management
87/100
Analyst Sentiment
65/100
Technical Momentum
50/100
Insider Confidence
60/100
News Sentiment
78/100

Fundamental Analysis

DD's fundamental profile remains bifurcated. Profitability: gross margin 31.6% (acceptable for specialty chemicals), operating margin 14.4% (solid), but net margin 4.3% (poor — massive below-the-line charges, likely PFAS litigation reserves and restructuring consuming ~10 percentage points). ROE 2.1% is deeply inadequate versus cost of capital (~8-10%), indicating ongoing economic value destruction at the GAAP level. FCF of $883M is the redeeming figure — capitalizing at a 7-8% discount rate implies enterprise value of $11-12.6B. Financial health is genuine: D/E 0.23x (industry 0.87x), cash $1.652B, FCF $883M — a fortress balance sheet. Valuation is the critical problem: P/E 69.92x (even after collapsing from 333x) versus industry average 24.90x (+180.8% premium). PEG 3.29x versus industry 2.91x (+12.9% premium) — marginally better on a relative basis. EPS growth (YoY) of -31.5% is a severe red flag contradicting the forward projection of +21.2% five-year CAGR. Revenue growth 4.1% lags industry 13.08% significantly (-68.6%). The P/E normalization from 333x to 69.92x appears driven by EPS denominator recovery (earnings base normalizing post-PFAS charges) but the stock price has simultaneously risen +10%, meaning the valuation improvement is partially illusory at the equity level. At $154.70 with only $164.50 consensus target, there is 6.3% analyst-implied upside against meaningful downside risk if earnings disappoint.

News Sentiment

DuPont is quietly emerging as a standout performer in an otherwise struggling chemicals industry — but investors are paying a steep price for that privilege. The company just raised its full-year profit forecasts, citing unexpectedly strong demand from healthcare companies and aerospace manufacturers, two sectors that have proven far more resilient than the broader industrial economy. That guidance boost helped push DuPont's stock to $154.70, a 10% gain from just two weeks ago. The company also reported net sales of $1.9 billion, a 4% increase year-over-year, with organic growth running even hotter at 5% — suggesting real underlying business momentum beyond just pricing. But it's not all clear skies. Industry reports flag sluggish demand in Europe and China — two critical markets where DuPont has meaningful exposure — which could cap how fast the top line can grow. On the innovation front, DuPont made headlines for two product launches: new high-flow electrodeionization modules for ultra-pure water applications, and a collaboration with tech giants Microsoft and NobleAI to accelerate research and development using artificial intelligence. These moves signal a company investing in its future rather than just managing current operations. The bottom line: DuPont is a quality business with real momentum — but at $154.70, with Wall Street's target only 6% higher, patient investors should wait for the stock to come back down before jumping in.

Risk Assessment

PRIMARY RISK: At $154.70, the stock offers only 6.3% upside to analyst consensus ($164.50) with downside risk of 15-25% if the earnings recovery story disappoints. The -31.5% YoY EPS decline makes the forward projections fragile. PFAS litigation tail risk is unresolved and structurally unpredictable — any large settlement announcement could reset the GAAP earnings base again. SECONDARY RISK: Weakness in Europe and China end markets (noted in news analysis) creates revenue growth headwinds that could pressure the 4.1% revenue growth even lower. Industry peers with 13.08% revenue growth are capturing share that DD is not. MITIGATION: The $883M FCF and $1.652B cash provide genuine downside cushion — the business won't face financial distress, and FCF supports the dividend. Any pullback to the $143-149 entry zone improves the risk/reward materially. At $146 entry vs. $164.50 target: ($164.50 - $146) / ($146 - $135) = $18.50 / $11 = 1.68x — improving to ~2.5x if the stock reaches $162-165 on earnings momentum. DO NOT CHASE at $154.70.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is DD a halal stock?

No, DuPont de Nemours, Inc. (DD) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for DD?

DuPont de Nemours, Inc. (DD) has a Plutrex AI rating of 58.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is DD a good investment?

According to Plutrex AI, DD has a Hold rating (58.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in DD?

US stocks like DD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in DD?

Plutrex AI identifies the main risks for DD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about DD

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open DD in ElBarake